Archive

Category Archives for "immunotherapy"

Scientists Discover New Way to Predict Immunotherapy Responses

coley's CPG

Immune checkpoint inhibitors like Keytruda offer new ways to treat cancer patients who might otherwise have no options. But the treatment has posed challenges to health care professionals when it comes to figuring out which tumors will respond to immunotherapy and which tumors won’t. A research team at Memorial Sloan Kettering Cancer Center in New […]

Continue reading

Immunotherapy in 2019: What’s Next for this Cancer Treatment?

immunotherapy

2018 saw tremendous improvements in immunotherapy methods that led to positive results for cancer patients all around the United States. 2019 promises even more advancements, and new strategies aim to increase these effective responses. The key to garnering even better immunotherapy results in 2019 will be using combination therapies. Two methods in particular will be front […]

Continue reading

Immunotherapy Efficacy in Patients with Metastatic Bladder Cancer

immunotherapy and bladder cancer

In the past several years, many checkpoint inhibitors have been approved by the FDA for use in treating patients with metastatic bladder cancer. These drugs offer new options for doctors who are treating these patients, but they also pose the challenge of determining the best order in which to use them. Joaquim Bellmunt, MD, Ph.D., […]

Continue reading

New Immunotherapy Guidelines Will Help Clinicians Treat Lung Cancer

immunotherapy

After the FDA approved Opdivo to treat non-small cell lung cancer (NSCLC) in March of 2015, it replaced cytotoxic chemotherapy as the main method of treatment for the disease. Immunotherapy has since become preferable to chemotherapy, as many new checkpoint inhibitors have also been FDA-approved. But because many immunotherapy treatments were introduced to the lab […]

Continue reading

On the Brink of Curing Cancer: How Nobel Prize Winners Offer Hope

integrative oncology

  The way we understand cancer treatment in the U.S. is changing. This year’s Nobel prizes in medicine honored new scientific breakthroughs that suggest we may be close to finding a cure for cancer. One of the Nobel-prize winners, Dr. James P. Allison, has made great strides in advancing cancer immunotherapy. Immunotherapy is a treatment […]

Continue reading

Improving Immunotherapy’s Success: The Power of NK Cells and SDCs

immune system

A recent study published in Nature Medicine reveals new ways to determine which cancer patients will respond best to immunotherapy with checkpoint inhibitors. This kind of therapy has shown great potential in effectively removing malignancies in about 20 to 40 percent of patients with cancers like melanoma, but there are still many patients whose cancer […]

Continue reading

Cancer Immunotherapy Acknowledged with 2018 Nobel Prize!

In what many are hailing as a paradigm shift in the treatment of cancer, The Nobel Prize in Physiology or Medicine was awarded to James P. Allison of the United States and Tasuku Honjo of Japan for their cutting-edge, exceptional work in developing cancer immunotherapy treatments. Allison, age 70, is from Alice, Texas and currently […]

Continue reading

Establishment of Immuno-oncology as a Cancer Therapy

immno-oncology

Immuno-oncology is set to become one of the most vital cancer treatments, rising up into the realms surgery, chemotherapy, radiotherapy, and other targeted therapies. From their study, “Pharma Focus Visual Analysis of Immuno-Oncology Development and Opportunities”, Global Data was able to reach a conclusion and has analyzed more than 4,000 clinical trials of over 800 […]

Continue reading

First Patient Receives Phase 1 Clinical Trial Dose of FS118

clinical trial

  The clinical trial for an antibody designed to treat advanced cancers has begun with the first dose of FS118. The treatment is supposed to target two immune checkpoint proteins. The study, based in the US, will be enrolling 51 patients who have been diagnosed with metastatic cancers. The patients have not previously responded to […]

Continue reading